HAVCR2 and non-small cell lung carcinoma: Other authors proposed that the novel targets for immunotherapeutic drug combinations and the treatment of NSCLC through the galectin-9/TIM-3 pathway and mMDSCs were key to anti-PD-1 primary or secondary resistance (52).